The combination of hepatitis B immunoglobulin (HBIG) and nucleos (t) ide analogues [NA
(s)] is considered as the standard of care for prophylaxis against HBV recurrence after liver …

A combination of hepatitis B immunoglobulin (HBIG) and nucleos (t) ide analogues (NUCs)
is currently recommended as prophylaxis against the recurrence of hepatitis B virus (HBV) …

Chronic hepatitis B is one of the most common infectious diseases worldwide. In patients
with an impaired immune system the prevalence of HBsAg is even higher and the course of …

Antiviral therapy using newer nucleos (t) ide analogues with lower resistance rates, such as
entecavir or tenofovir, suppress hepatitis B virus (HBV) replication, improve liver function in …

Liver transplant recipients are at risk of developing recurrent hepatitis B after liver
transplantation for hepatitis B virus (HBV)‐related liver disease. We evaluated the efficacy of …

The progress in treatment against hepatitis B virus (HBV) has substantially improved the
outcome of all HBV‐infected patients. We systematically reviewed the existing data in the …

Hepatitis B virus (HBV) infection continues to be a worldwide public health problem. In
Mexico, at least three million adults are estimated to have acquired hepatitis B (total hepatitis …

Background. Tenofovir therapy has been found to be efficient in treating hepatitis B virus
(HBV) in nontransplant patients. However, in the setting of solid-organ transplantation, the …

Methods Between 2006 and May 2011, approximately 145 patients undergoing HBV-related
LT and receiving entecavir plus low-dose, on-demand HBIg were enrolled and followed for a …

Introduction: The nucleotide analogue adefovir dipivoxil (ADV) was approved in 2002 for the
treatment of chronic infection with hepatitis B virus (HBV), in both hepatitis B e antigen …